| Journal | Current issues in molecular biology |
| Study Type | Clinical Study |
| Population | Human participants |
This comprehensive review maps how multiple neurotransmitter systems deteriorate in Alzheimer’s disease, providing clinicians with a mechanistic framework for understanding why current single-target therapies have limited efficacy. Understanding these interconnected pathways helps explain the complex symptom profile patients experience and may inform more effective treatment approaches.
This review synthesizes current understanding of neurotransmitter system dysfunction in Alzheimer’s disease beyond the traditional amyloid-tau framework. The authors detail how cholinergic degeneration correlates with cognitive decline, glutamatergic excitotoxicity accelerates neuronal damage through NMDA/AMPA receptor alterations, and GABAergic system disruption creates pathological hyperexcitability. The review emphasizes that AD involves simultaneous dysfunction across multiple neurotransmitter networks, not sequential failure of individual systems. While comprehensive, this is a narrative review rather than original research, limiting direct clinical applications.
“This reinforces what I see clinically – AD patients don’t fit into neat pharmacological boxes because multiple brain systems fail simultaneously. The multi-target dysfunction described here explains why single-mechanism drugs consistently disappoint in AD trials.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
How do neurotransmitter changes in Alzheimer’s disease affect cognitive symptoms?
Multiple neurotransmitter systems are disrupted in Alzheimer’s disease, with the cholinergic system showing early degeneration that directly correlates with cognitive impairment. The glutamatergic system exhibits excitotoxicity from excess extracellular glutamate, while GABAergic alterations in parvalbumin-positive interneurons lead to hyperexcitability, all contributing to progressive cognitive decline.
Why is the cholinergic system particularly important in Alzheimer’s disease treatment?
The cholinergic system was historically the first neurotransmitter system associated with Alzheimer’s disease and suffers early degeneration of neurons and receptors. This early involvement and its direct correlation with cognitive impairment makes it a primary target for current FDA-approved treatments like cholinesterase inhibitors.
What role does glutamate excitotoxicity play in Alzheimer’s disease progression?
In Alzheimer’s disease, the glutamatergic system experiences increased extracellular glutamate levels and altered NMDA/AMPA receptor distribution, leading to excitotoxicity. This excessive stimulation exacerbates neuronal damage and contributes to the progressive brain degeneration characteristic of the disease.
How do GABA system changes contribute to Alzheimer’s symptoms?
The GABAergic system, which normally provides inhibitory balance in the brain, shows alterations in parvalbumin-positive interneurons in Alzheimer’s disease. These changes lead to neuronal hyperexcitability, disrupting the normal excitatory-inhibitory balance and potentially contributing to both cognitive and behavioral symptoms.
Does this research suggest new therapeutic approaches beyond current Alzheimer’s medications?
This comprehensive understanding of multiple neurotransmitter system dysfunction suggests that multi-target therapeutic approaches may be more effective than single-system interventions. Current treatments primarily target cholinergic and glutamatergic systems, but addressing GABAergic dysfunction and the complex interplay between systems could offer new therapeutic opportunities.
